Alisertib (MLN8237)

For research use only. Not for use in humans.

目录号：S1133 中文名称：阿利色替

CAS No. 1028486-01-2

Alisertib (MLN8237)是一种选择性Aurora A抑制剂，无细胞试验中IC50为1.2 nM，作用于Aurora A比作用于Aurora B选择性强200倍以上。Alisertib 可诱导细胞周期阻滞、细胞凋亡与自噬。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1375.12	现货
5mg	RMB 983.87	现货
10mg	RMB 1725.78	现货
50mg	RMB 5505.84	现货
200mg	RMB 14496.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Alisertib (MLN8237)发表文献246篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2016, 22(7):744-53

PubMed: 27213815 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

PLoS Genet, 2021, 17(4):e1009327

PubMed: 33901174 ( click the link to review the publication )

Cancer Commun (Lond), 2021, 10.1002/cac2.12125

PubMed: 33471959 ( click the link to review the publication )

Mol Cell Endocrinol, 2021, 528:111243

PubMed: 33716050 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01019-9

PubMed: 33409897 ( click the link to review the publication )

Sci Rep, 2021, 11(1):2616

PubMed: 33510346 ( click the link to review the publication )

EMBO Rep, 2021, e51030

PubMed: 33615693 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Oncogene, 2020, 16

PubMed: 32300176 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2498

PubMed: 32899210 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )
Am J Cancer Res, 2020, 10(10):3406-3414

PubMed: 33163279 ( click the link to review the publication )

Mol Cancer Res, 2020, 8

PubMed: 32269073 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.1226.2019

PubMed: 32591441 ( click the link to review the publication )

Front Oncol, 2020, 10:1354

PubMed: 32974133 ( click the link to review the publication )

J Cell Sci, 2020, 133(24)jcs240267

PubMed: 33376154 ( click the link to review the publication )

Dis Model Mech, 2020, dmm.44289

PubMed: 32571902 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6690

PubMed: 32932728 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3424-3435

PubMed: 32595135 ( click the link to review the publication )

J Cancer, 2020, 11(8):2241-2251

PubMed: 32127951 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:857

PubMed: 33042987 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

CU Digital Repository, 2020, N/A

PubMed: N/A ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa570

PubMed: 32652013 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3485

PubMed: 31375684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5566

PubMed: 31804482 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2208

PubMed: 31101817 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3430-3442

PubMed: 30755439 ( click the link to review the publication )

Dev Cell, 2019, 50(3):355-366e6

PubMed: 31303441 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )
Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Rep, 2019, 26(2):293-301e7

PubMed: 30625311 ( click the link to review the publication )

Oncogene, 2019, 38(1):73-87

PubMed: 30082913 ( click the link to review the publication )

EBioMedicine, 2019, 41:120-133

PubMed: 30799199 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):606

PubMed: 31406104 ( click the link to review the publication )

FASEB J, 2019, 33(4):4866-4882

PubMed: 30596512 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003

PubMed: 31257184 ( click the link to review the publication )

Curr Biol, 2019, 29(21):3563-3578

PubMed: 31668617 ( click the link to review the publication )

PLoS Negl Trop Dis, 2019, 13(5):e0007425

PubMed: 31095613 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(3):312-323

PubMed: 30485161 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2211

PubMed: 30778113 ( click the link to review the publication )

Int J Oncol, 2019, 55(4):938-948

PubMed: 31485600 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Target Oncol, 2019, 14(5):563-575

PubMed: 31429028 ( click the link to review the publication )

Oncotarget, 2019, 10(17):1649-1659

PubMed: 30899434 ( click the link to review the publication )

Oncogene, 2019, 38(40):6696-6710

PubMed: 31391550 ( click the link to review the publication )

Blood Adv, 2019, 3(21):3214-3227

PubMed: 31698452 ( click the link to review the publication )

J Vis Exp, 2019, (151)

PubMed: 31589210 ( click the link to review the publication )
Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Curr Biol, 2018, 28(21):3458-3468e5

PubMed: 30415701 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6594-6610

PubMed: 30181387 ( click the link to review the publication )

J Cell Biol, 2018, 217(1):107-116

PubMed: 29074706 ( click the link to review the publication )

Elife, 2018, doi: 107554/eLife38111

PubMed: 30070631 ( click the link to review the publication )

Thyroid, 2018, doi: 101089/thy20180183

PubMed: 30226440 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Oncogene, 2018, 37(22):2921-2935

PubMed: 29515234 ( click the link to review the publication )

Oncogene, 2018, 37(4):502-511

PubMed: 28967900 ( click the link to review the publication )

BMC Biol, 2018, 16(1):116

PubMed: 30336771 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):781

PubMed: 30013101 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2575-2585

PubMed: 30266802 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Mol Pharm, 2018, 15(8):3046-3059

PubMed: 29863884 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Apoptosis, 2018, 23(9-10):492-511

PubMed: 30027525 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

J Cancer, 2018, 9(12):2061-2071

PubMed: 29937924 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Int J Mol Med, 2018, 41(6):3629-3641

PubMed: 29512701 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )
Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )

Anticancer Res, 2018, 38(6):3471-3476

PubMed: 29848699 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35875-35890

PubMed: 30542505 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14017

PubMed: 30228302 ( click the link to review the publication )

Oncotarget, 2018, 9(16):12769-12780

PubMed: 29560108 ( click the link to review the publication )

SLAS Discov, 2018, 23(8):850-861

PubMed: 29742358 ( click the link to review the publication )

J Neurooncol, 2018, 137(3):481-492

PubMed: 29396807 ( click the link to review the publication )

R Soc Open Sci, 2018, 5(12):181303

PubMed: 30662739 ( click the link to review the publication )

Sci Transl Med, 2017, 9(372)

PubMed: 28077684 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8:14294

PubMed: 28220783 ( click the link to review the publication )

Clin Cancer Res, 2017, 10.1158/1078-0432

PubMed: 28073841 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 27593935 ( click the link to review the publication )

EBioMedicine, 2017, 24:43-55

PubMed: 29030058 ( click the link to review the publication )

Plant Physiol, 2017, 173(1):582-599

PubMed: 27879390 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(1):94-107

PubMed: 28848145 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28615297 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:1-19

PubMed: 28918096 ( click the link to review the publication )

Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):670-682

PubMed: 28235899 ( click the link to review the publication )
Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

J Cell Sci, 2017, 130(4):683-688

PubMed: 28069833 ( click the link to review the publication )

Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

J Biol Chem, 2017, 292(5):1910-1924

PubMed: 28028179 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4652-4672

PubMed: 29118925 ( click the link to review the publication )

Am J Transl Res, 2017, 9(3):845-873

PubMed: 28386317 ( click the link to review the publication )

BMC Cell Biol, 2017, 18(1):33

PubMed: 29141582 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(4):386-401

PubMed: 27396604 ( click the link to review the publication )

Oncotarget, 2017, 8(10):16669-16689

PubMed: 28035071 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(19):32117-32133

PubMed: 28389630 ( click the link to review the publication )

Sci Rep, 2017, 7(1):17978

PubMed: 29269934 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112313-112329

PubMed: 29348827 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19738-19759

PubMed: 28160569 ( click the link to review the publication )

Oncotarget, 2017, 8(41):69691-69708

PubMed: 29050234 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(59):100326-100338

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114474-114480

PubMed: 29383095 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92926-92942

PubMed: 29190967 ( click the link to review the publication )

Pharmaceuticals (Basel), 2017, 10(3)

PubMed: 29036881 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )
Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

Nat Commun, 2016, 7:11389

PubMed: 27091106 ( click the link to review the publication )

Nat Commun, 2016, 7:12674

PubMed: 27624869 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

J Med Chem, 2016, 59(15):7188-211

PubMed: 27391133 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2135

PubMed: 26962685 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(8):1574-87

PubMed: 26908596 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(12):3400-3411

PubMed: 27768280 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Cell Biochem, 2016, 117(6):1340-51

PubMed: 26529125 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):566-76

PubMed: 27082306 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):413-24

PubMed: 26713495 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:3473-84

PubMed: 27366084 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 475(3):251-6

PubMed: 27233613 ( click the link to review the publication )

Exp Hematol, 2016, 44(4):247-56

PubMed: 26724640 ( click the link to review the publication )

Mol Med Rep, 2016, 14(1):394-8

PubMed: 27177156 ( click the link to review the publication )

Biol Bull, 2016, 231(1):61-72

PubMed: 27638695 ( click the link to review the publication )

Oncotarget, 2016, 7(22):33152-64

PubMed: 27121204 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84718-84735

PubMed: 27713168 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )
Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

J Cell Biol, 2015, 210(1):45-62

PubMed: 26124292 ( click the link to review the publication )

Mol Cancer, 2015, 14(1):83

PubMed: 25889801 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(9):2292-2300

PubMed: 25848977 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: 25395580 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):516-26

PubMed: 25501815 ( click the link to review the publication )

J Cell Sci, 2015, 128(20):3769-80

PubMed: 26349807 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2015,

PubMed: 26729093 ( click the link to review the publication )

Breast Cancer Res Tr, 2015, 149(3):715-26

PubMed: 25667100 ( click the link to review the publication )

Cell Cycle, 2015, 14(24):3908-19

PubMed: 26697841 ( click the link to review the publication )

Cell Cycle, 2015, 14(9):1447-58

PubMed: 25789545 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:575-601

PubMed: 25632225 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35247-62

PubMed: 26497213 ( click the link to review the publication )

Clin Cancer Res, 2014, 34(5):2269-74

PubMed: 24778030 ( click the link to review the publication )

Oncogene, 2014, 33(42):4985-96

PubMed: 24166501 ( click the link to review the publication )

Oncogene, 2014, 33(27):3550-60

PubMed: 23955083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )
Endocr Relat Cancer, 2014, 21(5):797-811

PubMed: 25074669 ( click the link to review the publication )

Mol Oncol, 2014, 8(8):1419-28

PubMed: 24953013 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2719-2729

PubMed: 25090971 ( click the link to review the publication )

J Transl Med, 2014, 12(1):200

PubMed: 25082261 ( click the link to review the publication )

Mol Carcinog, 2014, 10.1002/mc.22223

PubMed: 25284017 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

FEBS Lett, 2014, 588(14):2198-205

PubMed: 24857377 ( click the link to review the publication )

Chembiochem, 2014, 15(3):443-50

PubMed: 24403173 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113989

PubMed: 25436453 ( click the link to review the publication )

PLoS One, 2014, 9(3):e92402

PubMed: 24642638 ( click the link to review the publication )

PLoS One, 2014, 9(12):e116048

PubMed: 25545367 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101222

PubMed: 24983972 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

PLoS One, 2014,

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):845-51

PubMed: 25218503 ( click the link to review the publication )

Neurosci Lett, 2014, 583:199-204

PubMed: 25263789 ( click the link to review the publication )

J Pediatr Surg, 2014, 49(1):159-65

PubMed: 24439602 ( click the link to review the publication )

Oncotarget, 2014, 5(10):2947-61

PubMed: 24930769 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6229-42

PubMed: 25153724 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4071-86

PubMed: 24901229 ( click the link to review the publication )

Nat Commun, 2013, 4:2656

PubMed: 24141283 ( click the link to review the publication )
EMBO Mol Med, 2013, 5(1):149-66

PubMed: 23180582 ( click the link to review the publication )

Leukemia, 2013, 27(3):560-8

PubMed: 22940834 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(19):E1779-87

PubMed: 23610398 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

J Cell Biol, 2013, 202(3):463-78

PubMed: 23918938 ( click the link to review the publication )

EMBO Rep, 2013, 14(9):829-36

PubMed: 23887685 ( click the link to review the publication )

Int J Cancer, 2013, 135(3):751-62

PubMed: 24382688 ( click the link to review the publication )

Oral Oncol, 2013, 49(6):551-9

PubMed: 23481312 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(7):1451-9

PubMed: 23597309 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 6):1355-65

PubMed: 23345402 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 9):2102-13

PubMed: 23532825 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1833(10):2220-32

PubMed: 23707954 ( click the link to review the publication )

Epigenetics Chromatin, 2013, 6(1):21

PubMed: 23829974 ( click the link to review the publication )

J Biol Chem, 2013, 289(1):74-88

PubMed: 24273164 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64306

PubMed: 23717592 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23328114 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27670-81

PubMed: 22753416 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 135(2):433-44

PubMed: 22825030 ( click the link to review the publication )

Cell Cycle, 2012, 11(2):296-309

PubMed: 22214762 ( click the link to review the publication )

Cell Cycle, 2012, 11(13):2567-77

PubMed: 22722494 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30734

PubMed: 22359551 ( click the link to review the publication )

EMBO J, 2011, 30(5):906-19

PubMed: 21297582 ( click the link to review the publication )
Mol Cancer, 2011, 10:131

PubMed: 22011530 ( click the link to review the publication )

Oncotarget, 2011,

PubMed: 21865609 ( click the link to review the publication )

J Cell Biol, 2010, 191(7):1315-32

PubMed: 21187329 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):977-84

PubMed: 21072059 ( click the link to review the publication )

ACS Chem Biol, 2010, 5(6):563-76

PubMed: 20426425 ( click the link to review the publication )

Expert Opin Emerg Dr, 2010, 15(4):615-34

PubMed: 20690888 ( click the link to review the publication )

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述

特性

MLN8237 是第一个口服有效的小分子Aurora A激酶选择性抑制剂。

靶点

Aurora A ^[1]
(Cell-free assay)

1.2 nM

体外研究

MLN8237作用于Aurora A选择性比作用于结构相关的Aurora B 高200多倍，IC50为396.5 nM, 而对205种其他激酶则没有显著活性。^[1] 0.5 μM MLN8237处理MM1.S和 OPM1 细胞，抑制 Aurora A磷酸化，而不影响 Aurora B调节的组蛋白H3磷酸化。MLN8237作用于多发性骨髓瘤(MM) 细胞系，显著抑制细胞增殖，IC50为0.003-1.71 μM。在BM 基质细胞，IL-6和 IGF-1 存在时，MLN8237作用于原代MM 细胞和MM细胞系，抗增殖活性比只有MLN8237单独作用时高很多。0.5 μM MLN8237 作用于原代MM细胞和细胞系，使G2/M 期细胞提高2到6倍，且显著诱导凋亡和衰老，涉及p53, p21 和p27的上调,及 PARP,caspase 3,和 caspase 9的裂解。此外, MLN8237和 Dexamethasone联用具有协同作用，具有强抗MM 功效, 而和Doxorubicin 及Bortezomib联用则具有另外的功能。^[2] 0.5 μM MLN8237处理 FLO-1, OE19, 和OE33 食管腺癌细胞系，抑制集落形成，且显著提高多倍体细胞百分数,随后提高G1期细胞百分数,而与 Cisplatin (2.5 μM)联用则效果进一步提高，与单独用药相比，诱导产生更多, TAp73β, PUMA, NOXA, cleaved caspase-3, 和cleaved PARP。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXqwMlUh\|ryP	M3GyPFczKGh?	M2Ltc2ROW09?	NYPGOHBjUUN3ME2wMlA1KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
LS174T	NFr2fYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6wMlUh\|ryP	MlPkO\|IhcA>?	MknMSG1UVw>?	M{TtUWlEPTB;MD6wOUDPxE1?	M1jxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
T84	NU\nNFUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXznXZg2OC53IN88US=>	NUW4RlNIPzJiaB?=	M{\Pe2ROW09?	NG\5XZhKSzVyPUCuNFkh\|ryP	MnHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
LS180	NF3wRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDjNE42KM7:TR?=	NX3jRnZyPzJiaB?=	NXLkOpAzTE2VTx?=	MVTJR\|UxRTFizszN	MoG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
SW948	NUPNboFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkWxNE42KM7:TR?=	Ml7oO\|IhcA>?	MYjEUXNQ	MkjRTWM2OD1zIN88US=>	Mo\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
HCT15	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXmwMlUh\|ryP	MlHOO\|IhcA>?	NFj3eIxFVVOR	M1TPVWlEPTB:MD60JO69VQ>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
DLD-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYewMlUh\|ryP	MYS3NkBp	MnHPSG1UVw>?	M4fyV2lEPTB:MD64JO69VQ>?	Mn7iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
MIP-101	M{LyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[xc4UxNjVizszN	MmLqO\|IhcA>?	MVPEUXNQ	MoPsTWM2OD1zIN88US=>	M1;OdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
SNU1544	NVHJcmxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVWyUoEyOC53IN88US=>	NGOwPFY4OiCq	M4PyTGROW09?	NVjpcI4{UUN3ME2xJO69VQ>?	M3fzOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
OCI-Ly10	NH[3T\|BEgXSxdH;4bYMhSXO\|YYm=		NGPk[2w4OiCq	NXn3dXJxTE2VTx?=	M{XK[WlEPTB;MD6wOVgh\|ryP	MlPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
SU-DHL2	MkXjR5l1d3SxeHnjJGF{e2G7		M1TvR\|czKGh?	Mn23SG1UVw>?	NGG1e2NKSzVyPUCuNFEh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
OCI-LY7	NYrTb3BqS3m2b4TvfIlkKEG\|c3H5		NYPxbY1yPzJiaB?=	NGO4WIRFVVOR	MYDJR\|UxRTBwMEixJO69VQ>?	NH7pe2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
SU-DHL6	NVvMTItLS3m2b4TvfIlkKEG\|c3H5		NWnvN4F1PzJiaB?=	Ml3YSG1UVw>?	NWfOfpdpUUN3ME2wMlQ5OiEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Jeko-1	MnO2R5l1d3SxeHnjJGF{e2G7		MUe3NkBp	NYntSYE{TE2VTx?=	Mn;lTWM2OD1yLkCyPUDPxE1?	NID1RYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
JVM-2	MkXLR5l1d3SxeHnjJGF{e2G7		M37yUVczKGh?	MVrEUXNQ	Ml\lTWM2OD1yLkCxJO69VQ>?	M1jXUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
Rec-1	M4rIN2N6fG:2b4jpZ{BCe3OjeR?=		M3;ZSFczKGh?	M1jx[mROW09?	NHTsW3VKSzVyPUCuNFg4KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Z-138	MWrDfZRwfG:6aXOgRZN{[Xl?		MX[3NkBp	NXTLdpZGTE2VTx?=	M3rkcWlEPTB;MD6wNVMh\|ryP	M2TtZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
H9	NWnqfGV4S3m2b4TvfIlkKEG\|c3H5		M3HFNFczKGh?	M37P[WROW09?	NXOyfVhMUUN3ME2wMlYh\|ryP	NVLZN4duRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
HH	MVvDfZRwfG:6aXOgRZN{[Xl?		M{TDbFczKGh?	NUjCbFJZTE2VTx?=	MWLJR\|UxRTBwNzFOwG0>	MlfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
DND41	NXHhfmpqS3m2b4TvfIlkKEG\|c3H5		MUS3NkBp	MkPKSG1UVw>?	NGjxS5NKSzVyPUCuNUDPxE1?	NYT3XG9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
CCL119	NV\xZYFNS3m2b4TvfIlkKEG\|c3H5		MnPnO\|IhcA>?	MXHEUXNQ	MXfJR\|UxRTBwME[yJO69VQ>?	M{TqeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
J.Cam 1.6	NVTIbZFyS3m2b4TvfIlkKEG\|c3H5		M33GNFczKGh?	NYK0Nos{TE2VTx?=	MmD5TWM2OD1yLkGwOUDPxE1?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Sup-T1	MXTDfZRwfG:6aXOgRZN{[Xl?		NY\zcXhMPzJiaB?=	MX3EUXNQ	MkK5TWM2OD1{LkG0NkDPxE1?	NXzPfVJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
Tib 152	M{H4UmN6fG:2b4jpZ{BCe3OjeR?=		M1XFeFczKGh?	M3L0OGROW09?	M{LXOWlEPTB;MD64JO69VQ>?	NGjwOJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
MCF7	MWrGeY5kfGmxbjDBd5NigQ>?	NGjtcWs2KM7:TR?=	NETrdZMzPCCq	MVXEUXNQ	NI[zVI9KdmS3Y3XzJGczN01iYYLy[ZN1	NXLsXWIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	MVjGeY5kfGmxbjDBd5NigQ>?	MWe1JO69VQ>?	M2jqcVI1KGh?	NFXYclBFVVOR	MWDJcoR2[2W\|IFezM20h[XK{ZYP0	NHvzXFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MCF7	M1LwZmZ2dmO2aX;uJGF{e2G7	NGnWOJM2KM7:TR?=	MW[yOEBp	M1fWTmROW09?	NFToPGtF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy	NXvQeXU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	M17SWGZ2dmO2aX;uJGF{e2G7	MnrxOUDPxE1?	NFXKOIYzPCCq	MXfEUXNQ	NHHjcm5F\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>?	NYG1V5MzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	NYrud4FPTnWwY4Tpc44hSXO\|YYm=	MnTEOUDPxE1?	NFfCN4IzPCCq	MlPGSG1UVw>?	M3rTeWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG=	NVvUZoNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	M{DyXGZ2dmO2aX;uJGF{e2G7	NUDxbWpiPSEQvF2=	NVK4Z\|REOjRiaB?=	M{XXRmROW09?	MmnpTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	NEXrUlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MCF7	NUHFbXUxTnWwY4Tpc44hSXO\|YYm=	MX[1JO69VQ>?	MnHzNlQhcA>?	M3PuXGROW09?	M3X6TWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?=	NGHleog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	Mk[4SpVv[3Srb36gRZN{[Xl?	NI\mT3o2KM7:TR?=	M2nRTVI1KGh?	NX62dIpxTE2VTx?=	MnvSSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET\|EwS0SFMh?=	MofzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MDA-MB-231	MojzSpVv[3Srb36gRZN{[Xl?	NWXZbWx{OSEQvF2=	NULySJNbOjRiaB?=	MmDlSG1UVw>?	M4i3eWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	Mnz2SpVv[3Srb36gRZN{[Xl?	MkPHOUDPxE1?	NXjBU4U3OjRiaB?=	MkLXSG1UVw>?	Mn\3SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?=	NHLN[IY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	NEnSPGdHfW6ldHnvckBCe3OjeR?=	Mlm2OUDPxE1?	Ml;ZNlQhcA>?	MmLZSG1UVw>?	MlPZTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	NEHYVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	NYC0d4lzTnWwY4Tpc44hSXO\|YYm=	NWTme3FWPSEQvF2=	MXeyOEBp	NESyT\|VFVVOR	M3nGb2lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	M1TXS2Z2dmO2aX;uJGF{e2G7	NGLTNnI2KM7:TR?=	MoPhNlQhcA>?	M1n3[2ROW09?	Mny2TY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=>	MlvHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MCF7	MlG4RZBweHSxc3nzJGF{e2G7	MnPKOUDPxE1?	M1jM[lI1KGh?	MYrEUXNQ	M3vaXGlv\HWlZYOgZZBweHSxdHnjJIRm[XSq	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	MlewRZBweHSxc3nzJGF{e2G7	NYTVcIRGPSEQvF2=	MlnwNlQhcA>?	Moj6SG1UVw>?	NGPm[lJKdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	NXSyOFFnTnWwY4Tpc44hSXO\|YYm=	NGjWdosyKM7:TR?=	MmnQO\|IhcA>?	NXnjO\|FnTE2VTx?=	MX3JcoR2[2W\|IHH1eI9xcGGpaXOg[IVifGh?	MmrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MDA-MB-231	MXjGeY5kfGmxbjDBd5NigQ>?	NX\VSYVFOSEQvF2=	NWfVVpd{PzJiaB?=	MYTEUXNQ	M3nzTmlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?=	M321V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
U-2 OS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPWRoc2OCEQvF2=	Mnn6NlQhcA>?	NXO5ZlA4TE2VTx?=	M3XtXGlEPTB;MU[uOkDPxE1?	NWnTRZFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
MG-63	NVPxSpJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnCOVAh\|ryP	M1;oTlI1KGh?	NX\leII4TE2VTx?=	MVvJR\|UxRTlwNTFOwG0>	NIjiUnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NlgyOSd-MkW3PVI5OTF:L3G+
U-2 OS	NGjVNVdCeG:ydH;zbZMhSXO\|YYm=	NGnheJE2KM7:TR?=	MU[yOEBp	M1j0ZWROW09?	NWTH[4dKUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>?	NV7GPVluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
MG-63	NEHNRVFCeG:ydH;zbZMhSXO\|YYm=	NHjlZpA2KM7:TR?=	Ml[1NlQhcA>?	MmrZSG1UVw>?	NXPHNmdFUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>?	M3O4[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{myPFEyLz5{NUe5NlgyOTxxYU6=
U-2 OS	NXL0Uph6TnWwY4Tpc44hSXO\|YYm=	MYe1JO69VQ>?	Mn;CNlQhcA>?	MVrEUXNQ	MnLJVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	MlfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUK4NVEoRjJ3N{myPFEyRC:jPh?=
MG-63	M324N2Z2dmO2aX;uJGF{e2G7	M3zUWVUh\|ryP	MoLENlQhcA>?	M3XBNWROW09?	MWjQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MkixNUc,OjV5OUK4NVE9N2F-
PANC-1	NXHiSlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M371[FUxKM7:TR?=	NUjxNFVXOjRiaB?=	NEn0TIRFVVOR	MofZTWM2OD15LkGg{txO	NYHjWWxmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
BxPC-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3q1bFUxKM7:TR?=	MlPuNlQhcA>?	NHT4T\|NFVVOR	NGTxT5lKSzVyPU[uPEDPxE1?	NVjkfmN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
PANC-1	M4[5d2Z2dmO2aX;uJGF{e2G7	NGfFZ3A2KM7:TR?=	NIf1UpczPCCq	M1vhV2ROW09?	NETQfVdKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V?	M3TxR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
BxPC-3	MoC0SpVv[3Srb36gRZN{[Xl?	MnrROUDPxE1?	NWj0fZQ5OjRiaB?=	NGe3WmVFVVOR	MkjjTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpckBIOi:PIIDoZZNm	NXLBW3JWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
PANC-1	MYDGeY5kfGmxbjDBd5NigQ>?	M4TWdlUh\|ryP	MorWNlQhcA>?	MkTVSG1UVw>?	MX;JcoR2[2W\|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=>	NUjYO4dERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
BxPC-3	M{S4OmZ2dmO2aX;uJGF{e2G7	MmPWOUDPxE1?	M13SbVI1KGh?	M4W3XWROW09?	M3nCVmlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	NEjkeIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
SKOV3	NFzTeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfuNVAxKM7:TR?=	MV2yOEBp	NV65SpdzTE2VTx?=	NVvXT3hsUUN3ME2yNE41QCEQvF2=	NVGyc2NwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlQ4PTBpPkK1OlI1PzVyPD;hQi=>
OVCAR4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XxSFExOCEQvF2=	NVrVPYRoOjRiaB?=	NHrDfYVFVVOR	MnH1TWM2OD1{Mj6xN{DPxE1?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
SKOV3	NXLzclhjTnWwY4Tpc44hSXO\|YYm=	MorFOUDPxE1?	MX63NkBp	NF3KNodFVVOR	NHnZdoJKdmS3Y3XzJGczN01iYYLy[ZN1	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
OVCAR4	MmK4SpVv[3Srb36gRZN{[Xl?	MoruOUDPxE1?	M4jITFczKGh?	NHvxdY5FVVOR	MXjJcoR2[2W\|IFeyM20h[XK{ZYP0	M{fI[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK0O\|UxLz5{NU[yOFc2ODxxYU6=
SKOV3	MWLBdI9xfG:\|aYOgRZN{[Xl?	NYjoVGo5PSEQvF2=	M4PlcFI1KGh?	MYXEUXNQ	MlTiTY5lfWOnczDhdI9xfG:\|aYO=	MmC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkS3OVAoRjJ3NkK0O\|UxRC:jPh?=
OVCAR4	M4\QN2Fxd3C2b4Ppd{BCe3OjeR?=	M2iydlUh\|ryP	NXPPVXR6OjRiaB?=	Mn;iSG1UVw>?	Mn3jTY5lfWOnczDhdI9xfG:\|aYO=	MkPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkS3OVAoRjJ3NkK0O\|UxRC:jPh?=
AGS	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TLTVI2KM7:TR?=	NG\4TXQzPCCq	MkW1SG1UVw>?	NUO4[5c4UUN3ME2xPU4xQSEQvF2=	NX3UfJdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NFk6OjNpPkK1OlA6QTJ\|PD;hQi=>
NCI-N78	M3;iO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPjNogzPSEQvF2=	M2\OUFI1KGh?	M3rPV2ROW09?	MVnJR\|UxRTJ4LkOzJO69VQ>?	NF3JOIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[wPVkzOyd-MkW2NFk6OjN:L3G+
AGS	MnWyRZBweHSxc3nzJGF{e2G7	MnnJOUDPxE1?	NEnJRmwzPCCq	MXvEUXNQ	MkmzTY5lfWOnczDhdI9xfG:\|aYO=	M17JSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkC5PVI{Lz5{NU[wPVkzOzxxYU6=
NCI-N78	MknSRZBweHSxc3nzJGF{e2G7	M1PveFUh\|ryP	M1zUfFI1KGh?	NHL4VYVFVVOR	NVu5VFRiUW6mdXPld{BieG:ydH;zbZM>	Mm\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MEm5NlMoRjJ3NkC5PVI{RC:jPh?=
AGS	NVTHeYdXTnWwY4Tpc44hSXO\|YYm=	NH7tdlY2KM7:TR?=	NFfQRo0zPCCq	M4jtWWROW09?	M1PI[Wlv\HWlZYOgeIhmKGG3dH;wbIFogQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZyOUmyN{c,OjV4MEm5NlM9N2F-
NCI-N78	NXvZOWlbTnWwY4Tpc44hSXO\|YYm=	MkDROUDPxE1?	MnLGNlQhcA>?	M2r3c2ROW09?	NUjEbmRyUW6mdXPld{B1cGViYYX0c5Bp[We7	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZyOUmyN{c,OjV4MEm5NlM9N2F-
HSC-3	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVqxJO69VQ>?	M4LsblQ5KGh?		M{fGT2lEPTB;MD61OEDPxE1?	NF3pOFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2OlE1Oyd-MkWzOlYyPDN:L3G+
GB30	M4nyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn63NUDPxE1?	NWfTV4lZPyCm	MlTkSG1UVw>?	MlmwTWM2OD1yLkCxNUDPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNkSyPEc,OjVzME[0Nlg9N2F-
GB9	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2xJO69VQ>?	M3rrVFch\A>?	MYfEUXNQ	NEjnZ2hKSzVyPUCuNFI1KM7:TR?=	MlnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzME[0NlgoRjJ3MUC2OFI5RC:jPh?=
GB169	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWWxJO69VQ>?	M1ezcFch\A>?	MVzEUXNQ	MVfJR\|UxRTBwMEOyJO69VQ>?	NXe5[\|QxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFY1OjhpPkK1NVA3PDJ6PD;hQi=>
T24	M{TjbmZ2dmO2aX;uJGF{e2G7	MV2xJO69VQ>?	MlewOFghcA>?	NGXuV2JFVVOR	NGDKNZJKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0	NVjsdYp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzNpPkKzOFA{PjN\|PD;hQi=>
RT4	NUCzPHRCTnWwY4Tpc44hSXO\|YYm=	M1S3SFEh\|ryP	NEnPd2o1QCCq	MYrEUXNQ	NE\BbmRKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0	NEG3TGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN\|Y{Oyd-MkO0NFM3OzN:L3G+
UM-UC-3	MkXpSpVv[3Srb36gRZN{[Xl?	MlTjNUDPxE1?	MYK0PEBp	NVPx[mc2TE2VTx?=	M4rjcGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zN{c,OjN2MEO2N\|M9N2F-
T24	MXzBdI9xfG:\|aYOgRZN{[Xl?	NIHFN4Q{NjF4IN88US=>	NGXlVFU6PiCq	NELheZJFVVOR	M{nrcGlEPTB;MD6wN\|A3KM7:TR?=	NHW0Rlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN\|Y{Oyd-MkO0NFM3OzN:L3G+
RT4	NFXRc41CeG:ydH;zbZMhSXO\|YYm=	MWCzMlE3KM7:TR?=	NU\LWWhNQTZiaB?=	NGfSTm5FVVOR	MkXXTWM2OD1yLkGxPVgh\|ryP	MlnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEO2N\|MoRjJ\|NECzOlM{RC:jPh?=
UM-UC-3	NYPFfXpISXCxcITvd4l{KEG\|c3H5	MVizMlE3KM7:TR?=	NXXUflIxQTZiaB?=	MUXEUXNQ	M3LsVmlEPTB;MD6wOFQ6KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zN{c,OjN2MEO2N\|M9N2F-
OVCAR-5	NYH3TFI{TnWwY4Tpc44hSXO\|YYm=	NUTWNWVkPTBibl2=			MYjJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>?	NYTSdmF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzN\|Q{OjdpPkKzN\|M1OzJ5PD;hQi=>
SKOV3ip2	NETYRpNHfW6ldHnvckBCe3OjeR?=	MYG1NEBvVQ>?			M3XmfWlvcGmkaYTzJINmdGxibXnndoF1cW:w	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN\|NEOyO{c,OjN\|M{SzNlc9N2F-
S462	M1TFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYexNFAh\|ryP	NVLmN4lHPzJiaB?=	NIGycVhFVVOR	NXni[JVqSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?=	M2i2d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{K4NVE1Lz5{M{OyPFEyPDxxYU6=
2884	NI[1T41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULzWo4yOTByIN88US=>	MXm3NkBp	Mn;oSG1UVw>?	M2ThS2F1fGWwdXH0[ZMh[2WubDDndo94fGh?	NXzXXVR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNlgyOTRpPkKzN\|I5OTF2PD;hQi=>
2885	NYfhbm1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDB[GwyODBizszN	NHPnNoo4OiCq	NFfYSHNFVVOR	NV;Edm1wSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?=	MnLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MkixNVQoRjJ\|M{K4NVE1RC:jPh?=
CRL-2396	NGHnPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV[xNFAh\|ryP		NYjRNWVCf2G2ZYK=	NHLBSXhKSzVyPUCuNFkzKM7:TR?=	M32zSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUWzOVI1Lz5{M{G1N\|UzPDxxYU6=
TIB-48	NFuyN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPJPXY6OTByIN88US=>		NETWe5V4[XSnch?=	NYrZUmNVUUN3ME2wMlA5QCEQvF2=	MkLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUO1NlQoRjJ\|MUWzOVI1RC:jPh?=
CRL-2396	NYjLOmE4S3m2b4TvfIlkKEG\|c3H5	MUSxJO69VQ>?	M1:3OVQ5KGh?	MWX3ZZRmeg>?	NHPQUFJKdmS3Y3XzJIFxd3C2b4Ppdy=>	NGjGOnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G1N\|UzPCd-MkOxOVM2OjR:L3G+
TIB-48	NUjFXGttS3m2b4TvfIlkKEG\|c3H5	NFr4cHoyKM7:TR?=	M{TkeFQ5KGh?	M1vPRZdifGW{	NIDJfnNKdmS3Y3XzJIFxd3C2b4Ppdy=>	M{nGUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUWzOVI1Lz5{M{G1N\|UzPDxxYU6=
AGS	NWL5[G9xS3m2b4TvfIlkKEG\|c3H5	MYKwMlUh\|ryP	NU\ZbW9wOjRiaB?=	NInVNldFVVOR	NFPvdnhF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?=	NFT0Z2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm3NlYyOSd-MkK5O\|I3OTF:L3G+
FLO-1	M{nDWmN6fG:2b4jpZ{BCe3OjeR?=	MXSwMlUh\|ryP	MYqyOEBp	MXnEUXNQ	NWO1NGd7TGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy=	NGjidY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm3NlYyOSd-MkK5O\|I3OTF:L3G+
OE33	M1TaO2N6fG:2b4jpZ{BCe3OjeR?=	MX2wMlUh\|ryP	NX[2N2ZzOjRiaB?=	MUXEUXNQ	MUnE[YNz\WG\|ZYOgZ4VtdCC\|dYL2bZZidA>?	M4PWelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUeyOlEyLz5{Mkm3NlYyOTxxYU6=
SKLMS	NYK0XYRjS3m2b4TvfIlkKEG\|c3H5	M{LseFc2KG6P	MYm5OkBp		NH7ZOlNKdmS3Y3XzJIFxd3C2b4Ppdy=>	M4n2UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEKxPVk4Lz5{MkiyNVk6PzxxYU6=
Leio285	NEfXWJREgXSxdH;4bYMhSXO\|YYm=	NELvUVE4PSCwTR?=	M{\idFk3KGh?		NIHDcnNKdmS3Y3XzJIFxd3C2b4Ppdy=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{MUm5O{c,OjJ6MkG5PVc9N2F-
Mes-Sa	M2\1W2N6fG:2b4jpZ{BCe3OjeR?=	NInQNGM4PSCwTR?=	NHrPOlA6PiCq		MojKTY5lfWOnczDhdI9xfG:\|aYO=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{MUm5O{c,OjJ6MkG5PVc9N2F-
DAOY	NX7rZlZXS3m2b4TvfIlkKEG\|c3H5	NFzQdYYyOCEQvF2=	NGK5WWg4OiCq	M1XvcmROW09?	MnvUTWM2OD1yLkC0JO69VQ>?	MkLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NkmzN\|UoRjJ{Nk[5N\|M2RC:jPh?=
IMR32	NXK0T5RNS3m2b4TvfIlkKEG\|c3H5	NYnYe21tOTBizszN	MXW3NkBp	NEH6[3JFVVOR	NVHCPZMxUUN3ME2wMlA{KM7:TR?=	NH7ZfIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[2PVM{PSd-MkK2Olk{OzV:L3G+
Molt-4	MmCzR5l1d3SxeHnjJGF{e2G7	MUKxNEDPxE1?	MYW3NkBp	M{jHTWROW09?	NFjLdWtKSzVyPUCuNFIh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ4OUOzOUc,OjJ4NkmzN\|U9N2F-
MOLM-13	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWO3[ZVOOyEQvF2=	M4HWTFczKGh?		NWLLXYdbTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
HL-60	MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\DSFMh\|ryP	NGr1cmg4OiCq		M3\hc2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6OEK0PUc,OjJ2OEiyOFk9N2F-
MV4-11	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7tN{DPxE1?	NYr6dGNmPzJiaB?=		NEn2e3ZFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	M16wWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEi4NlQ6Lz5{MkS4PFI1QTxxYU6=
SKM-1	NYXvOXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVOzJO69VQ>?	NGfy[2E4OiCq		NYnSb5dWTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NFzSRpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
SH2	NWjQZ5h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzoRYc{KM7:TR?=	M32xT\|czKGh?		NXSy[mZOTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NVm2fYhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFgzPDlpPkKyOFg5OjR7PD;hQi=>
NOMO-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYqzJO69VQ>?	MX[3NkBp		NH30cVBFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6OEK0PUc,OjJ2OEiyOFk9N2F-
OCL-AML2	M1H4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDWUndxOyEQvF2=	MnPrO\|IhcA>?		NXv2XnFiTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NGLLTZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
PL-21	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDkd5U{KM7:TR?=	NH[ydok4OiCq		NHPRWZJFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6OEK0PUc,OjJ2OEiyOFk9N2F-
KG-1	NGPtZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXvN{DPxE1?	NHnIclU4OiCq		NUTqbWNHTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NH\zWFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
A172	MYrDfZRwfG:6aXOgRZN{[Xl?	MUWxNFAh\|ryP	MVuyOEBp	M3z6bmROW09?	NGSzcWpKSzVyPUCuNVIxKM7:TR?=	M3z1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
U87	M{O2UWN6fG:2b4jpZ{BCe3OjeR?=	MmX6NVAxKM7:TR?=	MUCyOEBp	MnXmSG1UVw>?	NFT0XWpKSzVyPUCuNVA2KM7:TR?=	NEXiZ4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
U251	NH\ZNVZEgXSxdH;4bYMhSXO\|YYm=	NFnVSFQyODBizszN	NX7qXZlHOjRiaB?=	MWDEUXNQ	M3PUfGlEPTB;MD6xNFAh\|ryP	M2DnRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
T98	NID4[4tEgXSxdH;4bYMhSXO\|YYm=	NELz[5YyODBizszN	M37sOlI1KGh?	M4TlPWROW09?	M1rLSWlEPTB;MD6xNlUh\|ryP	M163ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
LN18	MXrDfZRwfG:6aXOgRZN{[Xl?	NHLaTIYyODBizszN	M4DKSFI1KGh?	NH;J[WZFVVOR	MmS1TWM2OD1yLkKxNEDPxE1?	M4TwR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
LN443	NVzvN2loS3m2b4TvfIlkKEG\|c3H5	M{HIelExOCEQvF2=	NH3BNVAzPCCq	MoHZSG1UVw>?	NWPaNGZoUUN3ME2wMlIzOCEQvF2=	M{HiWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
HF66	M1:3Z2N6fG:2b4jpZ{BCe3OjeR?=	MYGxNFAh\|ryP	NG\6dVczPCCq	NH\kfo9FVVOR	MYnJR\|UxRTBwMkK1JO69VQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
HF2303	M2foUGN6fG:2b4jpZ{BCe3OjeR?=	M2TXdFExOCEQvF2=	MYiyOEBp	NYXKPVRQTE2VTx?=	MnnyTWM2OD1yLkC2NEDPxE1?	NGnKXZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
HF2359	NVvSOHQzS3m2b4TvfIlkKEG\|c3H5	MUOxNFAh\|ryP	MmfGNlQhcA>?	M3;wXWROW09?	MnTLTWM2OD1yLkC2NEDPxE1?	NYGwXFZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
HF2414	Mm\zR5l1d3SxeHnjJGF{e2G7	M{fWd\|ExOCEQvF2=	MmXUNlQhcA>?	NFLFS2hFVVOR	MXXJR\|UxRTBwMEiwJO69VQ>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
A-673	NIrxW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7vNVAh\|ryP	MoTRPVYhcA>?	NFW0cZRFVVOR	MmXzTWM2OD1yLkCzNkDPxE1?	NV\GU4pCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
TC-32	MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUGxNEDPxE1?	Ml7xPVYhcA>?	MXzEUXNQ	Mn;PTWM2OD1yLkCzPUDPxE1?	NUi4N3Z[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
TC-71	M3:w[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4ewR\|ExKM7:TR?=	NFT0SFQ6PiCq	NUDMXVhMTE2VTx?=	MmDqTWM2OD1yLkGwNkDPxE1?	M{XOZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SK-N-MC	NXvETHgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWixNEDPxE1?	NYX2clVQQTZiaB?=	M1LTTWROW09?	NULhbJptUUN3ME2wMlA4OiEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-9	NF3oT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHNNVAh\|ryP	MW[5OkBp	MnzYSG1UVw>?	Mn:zTWM2OD1yLkCxPEDPxE1?	M1rTSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-10	NUXGb5MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTVNVAh\|ryP	MX25OkBp	M{TiVWROW09?	NXqyT3NwUUN3ME2wMlA3OCEQvF2=	MnL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-25	MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELhbYsyOCEQvF2=	M{XsXlk3KGh?	M4jjVmROW09?	NVO3R4RxUUN3ME2wMlE3QCEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-32	NHXDS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOxNEDPxE1?	MnHMPVYhcA>?	M3v3O2ROW09?	NXz0VGg{UUN3ME2wMlE{PiEQvF2=	NWTkSHdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-56	M2\j[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYWxVINSOTBizszN	NXrmT2xnQTZiaB?=	NX\Bd3I3TE2VTx?=	MVfJR\|UxRTFyIN88US=>	M3:0XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-258	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvIVWgyOCEQvF2=	MWq5OkBp	NGflUGtFVVOR	Mn3xTWM2OD1yLkGzNkDPxE1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
COG-E-352	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDKbZBrOTBizszN	MY[5OkBp	MXXEUXNQ	M2XPWGlEPTB;MD6wOFMh\|ryP	NGfCepc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-90	M1vrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnf0NVAh\|ryP	NYTCOHhsQTZiaB?=	MWXEUXNQ	MkfETWM2OD1yLkC2NUDPxE1?	MnvUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-119	M2LIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7WNVAh\|ryP	M3HnbFk3KGh?	NVHXUJFqTE2VTx?=	M{HDeWlEPTB;MD6wNlIh\|ryP	NHvrbnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-122	M2jKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorINVAh\|ryP	MV[5OkBp	NVfLNlUzTE2VTx?=	MXnJR\|UxRTBwMEG5JO69VQ>?	NWjtb4dIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-136	NITRN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jIVlExKM7:TR?=	MYe5OkBp	NELrTnVFVVOR	M3Hy[GlEPTB;MD6wN\|kh\|ryP	MnnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-140	M4nTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;YNVAh\|ryP	MUW5OkBp	NFzVTYpFVVOR	NYDZOZhsUUN3ME2wMlAzPiEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
LA-N-6	NGS2OlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\1e3QyOCEQvF2=	MWm5OkBp	Mmq1SG1UVw>?	NU[5VHdIUUN3ME2wMlA2PCEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
NB-1643	NHf2fpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fOclExKM7:TR?=	M4G1elk3KGh?	NHnwcZVFVVOR	NETDe4JKSzVyPUCuNFM4KM7:TR?=	NF\rSZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
NB-EBc1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjnNHhrOTBizszN	MnTTPVYhcA>?	MnPsSG1UVw>?	MXzJR\|UxRTBwMEWwJO69VQ>?	M4r3TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SK-N-BE-1	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXq1Z2V{OTBizszN	M3;GS\|k3KGh?	MW\EUXNQ	NF\1T\|JKSzVyPUCuNFI5KM7:TR?=	M2fJUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SK-N-BE-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXWxNEDPxE1?	NYnLcXR[QTZiaB?=	NWLkdmpETE2VTx?=	NITmWZNKSzVyPUCuNFM3KM7:TR?=	NHzMWIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-KAN	NGXHW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHBNVAh\|ryP	MlPVPVYhcA>?	NFXQVpJFVVOR	NYqwe5FSUUN3ME2wMlA{PCEQvF2=	NVHLT3NSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-KANR	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWxNEDPxE1?	M3e3WVk3KGh?	NGPxbXNFVVOR	NH[5SHNKSzVyPUCuNFI3KM7:TR?=	NEL1W\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-KCN	M2rlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnx[XoyOCEQvF2=	NWLmTYM{QTZiaB?=	NVfsfXJ{TE2VTx?=	NIHtWJlKSzVyPUCuNFE6KM7:TR?=	NXXE[3BQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-KCNR	NWPoXHZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDiNVAh\|ryP	MXe5OkBp	MlLpSG1UVw>?	MVzJR\|UxRTBwMEGwJO69VQ>?	MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
SMS-LHN	M3HHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfRNFUyOCEQvF2=	M{LXVFk3KGh?	Mn7zSG1UVw>?	MVrJR\|UxRTBwMEOyJO69VQ>?	NXTWVXVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-MSN	NFLlXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fKflExKM7:TR?=	NYC3S4t5QTZiaB?=	MUDEUXNQ	NVn6OZI2UUN3ME2wMlAzOiEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
SMS-SAN	NUTaN\|MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\6dJR5OTBizszN	M{frUVk3KGh?	M1eyfmROW09?	M3rIc2lEPTB;MD6wNlAh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
Granta-4	MojqR5l1d3SxeHnjJGF{e2G7	M2m2fFExKM7:TR?=	NEjoOIY4KGR?		MVHJR\|UxRTBwMESwJO69VQ>?	M3GwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkmxPFY4Lz5{MUK5NVg3PzxxYU6=
DB	NEe3UmREgXSxdH;4bYMhSXO\|YYm=	Mmf1NVAh\|ryP	MlfEO{Bl		M{HFfmlEPTB;MD6wOFIh\|ryP	NV7NSoFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVE5PjdpPkKxNlkyQDZ5PD;hQi=>
RL	M{fUXWN6fG:2b4jpZ{BCe3OjeR?=	M33VdVExKM7:TR?=	NUH0XlFjPyCm		NHTpdGdKSzVyPUCuNFE2KM7:TR?=	NF\uPXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK5NVg3Pyd-MkGyPVE5Pjd:L3G+
K562	NUDrbJFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3qNVAh\|ryP	NVPyXJk{QTZiaB?=		NIqxemdKSzVyPUCuNFg4KM7:TR?=	NYKwXJB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPVE3OzNpPkKxNFkyPjN\|PD;hQi=>
LAMA-84	NHnWUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:xNEDPxE1?	MmnvPVYhcA>?		NYH2SlJTUUN3ME2wMlA2PyEQvF2=	NX\zd2x2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPVE3OzNpPkKxNFkyPjN\|PD;hQi=>
MM15	M1;kZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\6bVQh\|ryP	NHzYcYc4OiCq	MknRSG1UVw>?	M4nIfGlEPTB;MD6xN{DPxE1?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN6Mki0OEc,OjB\|OEK4OFQ9N2F-
OPM1	MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVu0JO69VQ>?	NHfIRmc4OiCq	MVXEUXNQ	NFPZUWNKSzVyPUCuNFMh\|ryP	NGfH[3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO4Nlg1PCd-MkCzPFI5PDR:L3G+
RPM1	M2PEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTHfnRyPCEQvF2=	MXW3NkBp	NVjR[WlpTE2VTx?=	NYf3ZXpRUUN3ME2xNE4{OiEQvF2=	MnTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
INA6	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUO0JO69VQ>?	NVHlNVZlPzJiaB?=	NU\5[\|FxTE2VTx?=	MkDoTWM2OD1yLkCwNkDPxE1?	NXrYR4o1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
OPM2	M1PtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\ld2Q1KM7:TR?=	M2roSVczKGh?	MXHEUXNQ	M{TNNGlEPTB;ND6zO{DPxE1?	NGPGcW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO4Nlg1PCd-MkCzPFI5PDR:L3G+
MM1R	M{fNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVK0JO69VQ>?	NV7HcJczPzJiaB?=	MnPzSG1UVw>?	NGrDNGxKSzVyPUGuOlgh\|ryP	NVHmU453RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
DOX40	NFzFPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13PV\|Qh\|ryP	MWe3NkBp	MWrEUXNQ	MoPvTWM2OD13LkS4JO69VQ>?	MkC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
LR5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:0JO69VQ>?	MWC3NkBp	NVvVdY1ETE2VTx?=	M4DhSmlEPTB;Mj61N{DPxE1?	M{jIWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
U266	NGLyb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU[0JO69VQ>?	M{LFe\|czKGh?	NYX0dWxCTE2VTx?=	MV3JR\|UxRTFwNEOg{txO	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN6Mki0OEc,OjB\|OEK4OFQ9N2F-
RD	NY\uPYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIP3elIyOCEQvF2=	MVW5OkBp		M{T4XWlEPTB;MD6yNlgh\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
Rh41	NXr6PIc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVyxNEDPxE1?	MkizPVYhcA>?		NGnhWZFKSzVyPUCuNFkxKM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
Rh30	M4X3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPPd2ZoOTBizszN	Mkj2PVYhcA>?		NETFeJdKSzVyPUCuNlMxKM7:TR?=	MnjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
BT-12	NVHtPWVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFS2cZIyOCEQvF2=	MnvOPVYhcA>?		M3mxeGlEPTB;MD6wOlAh\|ryP	Ml25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
CHLA-266	M17P[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;yZXcyOCEQvF2=	M3i4[\|k3KGh?		MXnJR\|UxRTBwMEeyJO69VQ>?	NWTGOItrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
TC-71	NYTVTY9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3KwbVExKM7:TR?=	MUi5OkBp		NHzaZVJKSzVyPUCuNVAzKM7:TR?=	M{T3OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
SJ-GBM2	MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX:xNEDPxE1?	M{HJU\|k3KGh?		NV\rbIhOUUN3ME2wMlA2OCEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
NALM-6	M37i[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfTemYyOCEQvF2=	MWG5OkBp		M1vX[WlEPTB;MD6wOlIh\|ryP	NUPyWW1jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
COG-LL-317	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXnOWQyOCEQvF2=	M3\xSlk3KGh?		Mkm1TWM2OD1yLkC0O{DPxE1?	MlG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
RS4-11	M1vj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYG2TmpUOTBizszN	M4XMT\|k3KGh?		NHntVJNKSzVyPUCuNFE5KM7:TR?=	M4CzUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
MOLT-4	NH7tdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzJ[GpoOTBizszN	NFXrZ3c6PiCq		NHvjU25KSzVyPUCuNFI3KM7:TR?=	NGPEUJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
CCRF-CEM	M3zHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVOxNEDPxE1?	M17ndFk3KGh?		M1vIU2lEPTB;MD6wPVQh\|ryP	NYjmdm5KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
Kasumi-1	NHTIT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVixNEDPxE1?	NXXSTYtlQTZiaB?=		M1LmemlEPTB;MD6xNFMh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
Karpas-299	NX:0W2c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfDflJ3OTBizszN	NEPxVY06PiCq		M4jMe2lEPTB;MD6wN\|gh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
Ramos-RA1	NGn1UXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXWxNEDPxE1?	M4\LeVk3KGh?		NGfYeWFKSzVyPUCuNVI4KM7:TR?=	NFvNWmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
GSS	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1e2UFczKGi{cx?=		MnjiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCJU2OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFeVVEigZZN{[XluIFnDOVAhRSByLkCzPUDPxE1w	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
LU99A	M{T2PGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3ntR\|czKGi{cx?=		MmDFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOVUm5RUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFYzKM7:TT6=	NVu3T2VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
HL60	NYjWbJFRSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NI[yW5Y4OiCqcoO=		NFfMPGpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGfTWFgh[XO\|YYmsJGlEPTBiPTCwMlA4PCEQvF2u	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
LC2/ad	M3LDdGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmTsO\|IhcHK\|		NHPCPFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzDNk9i\CClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvODd5IN88UU4>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
MKN45	NY\O[WhySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGr6bZY4OiCqcoO=		NIH3b\|hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4xQTNizszNMi=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
HCT116	M33tc2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVe3NkBpenN?		NWTWflFsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjB7NTFOwG0v	M4D6ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
Lu116	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mmr2O\|IhcHK\|		MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEy3MUG2JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wPVch\|ryPLh?=	NV;vTlZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
NCI-H358	NGTZcIFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYG3NkBpenN?		M2q0W2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{PThiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjFizszNMi=>	NHf4cVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
MIAPaCa2	NIq3TXNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIrO[3g4OiCqcoO=		MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQWDhR4EzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4yOyEQvF2u	NFjKO4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
PC14	Mo\IRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWm3NkBpenN?		M121fGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOxOEBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNVch\|ryPLh?=	Ml3jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
HT-29	NW\1dIVoSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUjYUFdxPzJiaILz		NED5TmJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4{OyEQvF2u	NFfqcI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
HCT15	M3HjUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2f0XVczKGi{cx?=		Mn7JRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxOUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuO\|Qh\|ryPLh?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
Sf9	M{izTGZ2dmO2aX;uJIF{e2G7				NIDEeXBEd22yZYTpeIl3\SCrbnjpZol1cW:wIH;mJJJm[2:vYnnuZY51KG2xdYPlJIF2em:{YTDrbY5ie2ViQTDlfJBz\XO\|ZXSgbY4hcW6\|ZXP0JHNnQSClZXzsd{BqdiCycnXz[Y5k\SCxZjDBWHAtKEurIE2gNE4xODB\|IN88UU4>	M3O1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUCxOVY1Lz5{NkGwNVU3PDxxYU6=
Sf9	MmfsSpVv[3Srb36gZZN{[Xl?				MmHhTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDtc5V{\SCjdYLvdoEhc2mwYYPlJGEh\XiycnXzd4VlKGmwIHnud4VkfCCVZkmgZ4VtdHNidYPpcoch[mmxdHnuMWdNWlKDU1zHJIF{KHO3YoP0doF1\SCrbjDwdoV{\W6lZTDv[kBc\2GvbXGtN\|NRZUGWUDygTWM2OCB;IECuNFAyKM7:TT6=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFyMUW2OEc,OjZzMEG1OlQ9N2F-
HCT116	NGXyWVBHfW6ldHnvckBie3OjeR?=				M3fqemlvcGmkaYTpc44hd2ZiYYXyc5JiKGurbnHz[UBCKGG3dH;wbI9{eGixconsZZRqd25iYYSgWFI5QCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZpkhcW2vdX7v[ox2d3Knc3PlcoNmKGGwYXz5d4l{NCCLQ{WwJF0hOC5yMEeg{txONg>?	M3ixSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUCxOVY1Lz5{NkGwNVU3PDxxYU6=
HCT116	MkezR5l1d3SxeHnjbZR6KGG\|c3H5				MkfuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGK7IFLy[HUhcW6lb4Lwc5JifGmxbjDhd5NigSxiR1m1NEA:KDBwMEOg{txONg>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFyMUW2OEc,OjZzMEG1OlQ9N2F-
HCT116	NUfOSJJjTnWwY4Tpc44h[XO\|YYm=				M3zlNWlvcGmkaYTpc44hd2ZiYYXyc5JiKGurbnHz[UBDKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHjpd5RwdmViSEOgdIhwe3Cqb4L5cIF1cW:wIHL5JIludXWwb3\seY9z\XOlZX7j[UBidmGueYPpd{whUUN3MDC9JFEvPSEQvF2u	M3zF[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUCxOVY1Lz5{NkGwNVU3PDxxYU6=
BL21 (DE3) Rosetta	MX3GeY5kfGmxbjDhd5NigQ>?		NFfPfHM{OCCvaX7z		NXPNd3NiUW6qaXLpeIlwdiCxZjDIbZMufGGpZ3XkJIh2dWGwIFH1do9z[SCDIHvpcoF{\SBqMUKyJJRwKDRyIILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzIDjESVMqKFKxc3X0eIEh[2WubIOgeZNqdmdiYnnveIlvgWyjdHXkJHNVUzJic4Xid5Rz[XSnIHnuZ5Vj[XSnZDDmc5IhOzBibXnud{BjgSCKVGLGJIF{e2G7LDDJR\|UxKD1iMD6wNFAxPCEQvF2u	MmL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|OUGxN\|MoRjJ5M{mxNVM{RC:jPh?=
HeLa Kyoto	M{DnZWZ2dmO2aX;uJIF{e2G7		NGXVbFYzOCCqcoO=		MlruTY5pcWKrdHnvckBw\iCDdYLvdoEhSiCtaX7hd4UhcW5iaIXtZY4hUGWOYTDLfY91dyClZXzsd{Bie3Onc4Pl[EBieyCnZn\lZ5Qhd25iZHnzeJJq[nW2aX;uJI9nKHCqc4Doc{1pcXO2b37lJGg{KHOnckGwJIxmfmWuIHnuZ5Vj[XSnZDDmc5IhOjBiaILzMEBKSzVyIE2gNE4xODF3IN88UU4>	NYPkbIppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVEyOzNpPkK3N\|kyOTN\|PD;hQi=>
HeLa Kyoto	MknOSpVv[3Srb36gZZN{[Xl?		NHjKTHMzOCCqcoO=		NXnNNHZRUW6qaXLpeIlwdiCxZjDBeZJwemFiQTDrbY5ie2ViYYX0c5Bpd3OyaH;yfYxifGmxbjDheEBVcHJ{OEigbY4hcHWvYX6gTIVN[SCNeX;0c{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDJyIHjyd{whUUN3MDC9JFAvODB4NzFOwG0v	NUXCdZJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVEyOzNpPkK3N\|kyOTN\|PD;hQi=>
multiple myeloma	M1[3emZ2dmO2aX;uJIF{e2G7				MoezV5VxeHKnc4Ppc44hd2ZiY3XscEBucXSxc3nzJIlvKGi3bXHuJI12dHSrcHzlJI16\WyxbXGgZ4VtdHNuIFnDOVAhRSByLkCwN{DPxE1w	NF74XY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmxPFA6Pid-Mki5NVgxQTZ:L3G+
Calu6	MmDIRY51cXS3bX;yJIF{e2G7	M3LobVIxKG2pL3vn	MnHINlEh\GG7cx?=		NVm2XGV2SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gR4FtfTZiY3XscJMhgGWwb3fyZYZ1\WRiaX6gcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgNlAhdWdxa3esJJBwKGKrZDDh[I1qdmm\|dHXy[YQh\m:{IEKxJIRigXN?	NYjBfVZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNFE2PjRpPkK2NVAyPTZ2PD;hQi=>
HeLa Kyoto	MV;GeY5kfGmxbjDhd5NigQ>?	MoCzNE4zPSC3TR?=	M2XzXlIxKGi{cx?=		NYXDUG5KUW6qaXLpeIlwdiCxZjDBeZJwemFiQTDrbY5ie2VibH;jZYxqgmG2aX;uJIF1KHOyaX7kcIUhdWmlcn;0eYJ2dGW\|IHnuJIh2dWGwIFjlUIEhU3mxdH:gZ4VtdHNiYYSgNE4zPSC3TTDpcoN2[mG2ZXSg[o9zKDJyIHjydy=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7MUGzN{c,Ojd\|OUGxN\|M9N2F-
MDA-MB-231	M2qxW2Z2dmO2aX;uJIF{e2G7	MXGxJJVO	NXfzfIJ6PDhiaILz		Mme0TY5lfWO2aX;uJI9nKGOqcn;tc5NwdWViYXzp[45u\W62IHTl[oVkfHNiaX6gbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKGmvbYXuc4ZtfW:{ZYPj[Y5k\SCjc4PhfS=>	NHXNT\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO1PFE1Pyd-MkmzOVgyPDd:L3G+
MDA-MB-231	MoK3SpVv[3Srb36gZZN{[Xl?	MUixJJVO	MmDSOFghcHK\|		MoDKTY5lfWO2aX;uJI9nKGGkZYLyZY51KHOyaX7kcIUh\m:{bXH0bY9vKHerdHigeJJqeG:uYYKgZY5lKHSndILhdI9t[XJib3PjeZJz\W6lZTDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiaX3teY5w\my3b4Lld4NmdmOnIHHzd4F6	MoHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
MDA-MB-231	NV7Ke4dZTnWwY4Tpc44h[XO\|YYm=	NFvld\|kxNjVidV2=	NV3SRoJKPDhiaILz		NG\mRWlKdmirYnn0bY9vKG:oIHHsdIhiNXS3YoXsbY4hcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCjYn;sbZNpdWWwdDDv[kBz\We3bHHyJIxw[2G2aX;uJI9nKHC{b4TlbY4h[XRiMD61JJVOKGGodHXyJFQ5KGi{czDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKGmvbYXuc4ZtfW:{ZYPj[Y5k\SCjc4PhfS=>	NEHzOm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO1PFE1Pyd-MkmzOVgyPDd:L3G+
MDA-MB-231	MXLGeY5kfGmxbjDhd5NigQ>?	NWDZcWQ{OC53IIXN	NVnONYZoPDhiaILz		MXLJcohq[mm2aX;uJI9nKEGXUlvBJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMh[WKxbHnzbI1mdnRib3[gdoVofWyjcjDsc4NifGmxbjDv[kBxem:2ZXnuJIF1KDBwNTD1UUBi\nSncjC0PEBpenNiYomgSGFRUSC\|dHHpcolv\yCkYYPl[EBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYm=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN3OEG0O{c,Ojl\|NUixOFc9N2F-
TC32	NYn1bFJueUiWUzDhd5NigQ>?				M{\KW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy\|	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MYXxTHRUKGG\|c3H5				NIfIU2RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	NXi5focyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NH\FNZVyUFSVIHHzd4F6				M4TmeZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	NFj1WnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	Mnf3dWhVWyCjc4PhfS=>				M2XZcZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	M1LNTZFJXFNiYYPzZZk>				M4jTO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	NU\nXIRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MXPxTHRUKGG\|c3H5				M1L3T5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN?	Mo[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	M2X1TJFJXFNiYYPzZZk>				MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	NEDUcVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	M37kcZFJXFNiYYPzZZk>				NHr0T2hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MWjxTHRUKGG\|c3H5				NYWyW4dTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	MkfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MkfkdWhVWyCjc4PhfS=>				NVfJ[212eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NWPzXJEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MXPxTHRUKGG\|c3H5				MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	NWHD[4tqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	NV24W2pQeUiWUzDhd5NigQ>?				NVLIXlNqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	NVzpNZRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NFrZXFhyUFSVIHHzd4F6				M1K4XJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	Mk\4dWhVWyCjc4PhfS=>				MoqwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	MkPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	MonBdWhVWyCjc4PhfS=>				NED1RYlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	M{jGUZFJXFNiYYPzZZk>				NE\uTodyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:\|LUKgZ4VtdHN?	NV[3VW5IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AURKA(T288) / p-EIF4E(S209) / c-Myc; PubMed: 28073841 Clin Cancer Res Inhibition of AURKA with alisertib downregulated p-EIF4E (S209) and c-MYC protein levels as assayed by Western blotting. phospho-Aurora A / Aurora B; PubMed: 22863010 Cell MLN8237differentially inhibited phosphorylation of Aurora kinases. CMK cells were incubated with 0.1 µM paclitaxel for 18 hr, then DMSO or MLN8237 was added and incubated for 2 hr. The degree of phosphorylation of the Aurora kinases in each sample was determined by Western blot. H3S10P / H3K27me2 / H3K27me3 / H3K9me2 / H3AcK / H4K16Ac; PubMed: 29477140 Mol Cells THP-1 cells were treated with alisertib or DMSO for 48 h. The levels of histone modifications were detected by western blot analysis with the indicated antibodies. H3 was used as a loading control.	28073841 22863010 29477140
Growth inhibition assay	Cell viability; PubMed: 25632225 Drug Des Devel Ther PANC-1 and BxPC-3 cells were treated with ALS at concentrations ranging from 0.1 μM to 50 μM for 24 hours. The viability of PANC-1 and BxPC-3 cells determined by MTT assay. ALS, alisertib.	25632225
Immunofluorescence	acetylated α-tubulin / γ-tubulin; PubMed: 29401581 FASEB J Representative immunofluorescence (IF) image and graph in human PKD1-mutant WT9-7, WT9-12 cells or hTERT-RPE1 (RPE1) cells after 2 hours treatment with vehicle, ganetespib , or alisertib to inhibit AURKA, or combination of alisertib and ganetespib. acetylated α-tubulin (red); γ-tubulin (green); DAPI (blue). Scale bars, 5 μm. E-cadherin / β-catenin / vimentin / p-SMAD5; PubMed: 23334326 Oncogene Immunofluorescence analysis of CD24 (-/low) cells treated with1 μM MLN8237 for 48 and 72 h showing reversion of EMT. E-cadherin and p-SMAD5 were labeled in red, β-catenin and vimentin were labeled in green, and DNA was labeled in blue with Hoechst dye. Centrin-2 / tubulin; PubMed: 30899434 Oncotarget Following inhibition of Aurora A kinase activity with 100 nM alisertib, cells with two or excess centrosomes similarly exhibit disorganized mitotic spindles. Cells with extra centrosomes are efficiently clustered into bipolar spindles prior to anaphase onset while those with supernumerary centrosomes undergo multipolar mitoses. Centrin-2, a marker of centrioles is shown in green, tubulin in red, and chromatin in blue. AurA inhibitor: alisertib. phospho-Aurora A(T288); PubMed: 20382844 Blood MM1.S cells were treated with DMSO or MLN8237 (0.5μM) for 24 hours and then stained with anti-phospho (Thr288)-Aurora-A kinase antibody (red), αtubulin (green), and DNA (blue). Overlapping localization is shown in the merged images. Arrow indicates Aurora-A autophosphorylation on Thr288 in the centrosome (original magnification ×40). Magnified single mitotic cell image is shown in the right panel.	29401581 23334326 30899434 20382844

体内研究

MLN8237口服处理，显著降低肿瘤负担，按15 mg/kg 和30 mg/kg剂量处理肿瘤生长抑制率(TGI) 分别为42%和80%,且与对照组相比，延迟小鼠寿命。^[2] MLN8237 (30 mg/kg) 与Cisplatin (2 mg/kg) 联用作用于FLO-1移植瘤，与单独用药相比，抗癌活性增强，伴随着Ki-67表达受抑制，细胞核p73蛋白和cleaved caspase 3表达增强。^[3]

激酶实验：^[1]	- 合并 Aurora A放射性闪光板酶实验: 进行Aurora A放射性闪光板酶实验，测定体外MLN8237抑制程度。在Sf9细胞中表达重组Aurora A，然后使用GST亲和层析进行纯化。Aurora A 肽底物与生物素联合形成生物素-GLRRASLG。在50 mM Hepes (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.05% Tween-20, 2 μM 肽底物, 3.3 μCi/mL [γ-³³ P]ATP 2 μM, 和浓度不断增高的MLN8237 的混合物中进行Aurora A激酶 (5 nM)实验。
细胞实验：^[2]	- 合并 Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, 和U266 Concentrations: 溶于DMSO,终浓度为~10 μM Incubation Time: 24, 48, 和72小时 Method: 使用不同浓度MLN8237处理细胞24, 48,和72小时。通过MTT实验测定细胞活力，通过测定 3[³H]-胸甘渗透而测定细胞增殖。为了分析细胞周期，使用70%乙醇在-20^oC下使细胞通透，然后与50 μg/mL PI 和20 单位/mL RNase-A温育。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件分析DNA含量。为了测定凋亡和衰老，使用异硫氰酸荧光素-annexin V和PI对细胞进行染色。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件测定凋亡细胞。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 皮下接种 MM1.S 细胞的SCID鼠 Dosages: ~30 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	27 mg/mL (52.03 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+30% PEG300+5%Tween-80+ddH2O	6mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Alisertib (MLN8237) SDF

分子量	518.92
化学式	C₂₇H₂₀ClFN₄O₄
CAS号	1028486-01-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04479306	Recruiting	Drug: Alisertib\|Drug: Osimertinib\|Drug: Sapanisertib	Recurrent Lung Non-Small Cell Carcinoma\|Stage IIIB Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	M.D. Anderson Cancer Center	June 18 2020	Phase 1
NCT02812056	Withdrawn	Drug: Alisertib\|Drug: TAK-228	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1
NCT02719691	Active not recruiting	Drug: Alisertib\|Drug: MLN0128	Metastatic Breast Cancer\|Solid Tumors	University of Colorado Denver	May 13 2016	Phase 1
NCT02367352	Terminated	Drug: Alisertib\|Drug: Paclitaxel	Advanced Solid Tumors\|Ovarian Cancer\|Small Cell Lung Cancer	Millennium Pharmaceuticals Inc.\|Takeda	March 19 2015	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the suggested formulation of this compound for mouse injection(i.p.)?
回答：
It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

泛Aurora Kinase抑制剂

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
泛Aurora Kinase抑制剂

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
活性最高的Aurora Kinase抑制剂

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
用于临床的Aurora Kinase抑制剂

VX-680 (Tozasertib, MK-0457) : Phase II for Advanced Non-Small Cell Lung Cancer (NSCLC).
经典的Aurora Kinase抑制剂

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

研究领域

产品类型

定制您的化合物库

Alisertib (MLN8237)

客户使用Selleck生产的Alisertib (MLN8237)发表文献246篇：

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Alisertib (MLN8237) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

常见问题及建议解决方法

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品